Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab for systemic sclerosis-associated pulmonary arterial hypertension
NL-OMON27131Phase 2Suspended
- Sponsor
- VU University Medical Center
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and systemic sclerosis (SSc), sponsored by VU University Medical Center. Primary endpoint: Safety. Started Jan 2007; status: suspended.
02
Drugs
cetuximab
03
Conditions
Scleroderma-associated pulmonary arterial hypertension (SSc-PAH)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON27131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27131.